Skip to main content

HIMS

Stock
Consumer Staples
Household & Personal Products

Performance overview

HIMS Price
Price Chart

Forward-looking statistics

Beta
1.62
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.

Company info

SectorConsumer Staples
IndustryHousehold & Personal Products
Employees861
Market cap$4.5B

Fundamentals

Enterprise value$10.9B
Revenue$1.8B
Revenue per employee—
Profit margin9.21%
Debt to equity11.54

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)$0.68
Dividend per share—
Revenue per share$8.18
Avg trading volume (30 day)$2B
Avg trading volume (10 day)$3B
Put-call ratio—

Macro factor sensitivity

Growth+1.8
Credit+4.8
Liquidity-0.7
Inflation-6.7
Commodities-1.9
Interest Rates-0.8

Valuation

Dividend yield0.00%
PEG Ratio104.30
Price to sales6.02
P/E Ratio104.30
Enterprise Value to Revenue6.11
Price to book19.53

Upcoming events

Next earnings dayMay 6, 2025
Next dividend day—
Ex. dividend day—

News

Hims & Hers Health, Inc. (HIMS) Stock Drops Despite Market Gains: Important Facts to Note

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $47.6, signifying a -5.52% move from its prior day's close.

Zacks Investment Research (July 21, 2025)
Bet on Winning DuPont Analysis & Pick 3 Top Stocks

Do you have more faith in DuPont analysis than simple ROE calculation? Tap AllianceBernstein (AB), Mama's Creations Inc. (MAMA) and Hims & Hers Health (HIMS).

Zacks Investment Research (July 21, 2025)
Novo Nordisk's Canadian drug patent lapses, opening market for Hims & Her Health

Hims and Hers Health is planning to cash in on Novo Nordisk losing its semaglutide drug exclusivity in Canada. The telehealth company, among others, will now be allowed to make exact copies of Novo's blockbuster weight loss drugs Ozempic and Wegovy starting in January 2026.

CNBC Television (July 9, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free